Showing 1-10 of about 48 articles.

Applied Therapeutics

Applied Therapeutics to be Added to NASDAQ Biotechnology Index

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

December 15, 2020

Applied Therapeutics

Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

December 09, 2020

Applied Therapeutics

Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

December 09, 2020 photo-release

Applied Therapeutics

Applied Therapeutics Reports Third Quarter 2020 Financial Results

Continued enrollment in the ARISE-HF Phase 3 global registrational study of AT-001 in Diabetic Cardiomyopathy (fatal heart disease affecting ~17% diabetics) On track to initiate rare disease...

November 12, 2020

Applied Therapeutics

Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2020

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

November 09, 2020

Applied Therapeutics

Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2020 Annual Meeting

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

October 21, 2020

Applied Therapeutics

FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG

NEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

September 24, 2020

Applied Therapeutics

Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at 56th Annual Meeting of the European Association for the Study of Diabetes

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

September 17, 2020

Applied Therapeutics

Applied Therapeutics to Present at Citi and Baird Investor Conferences

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

September 02, 2020

Applied Therapeutics

Applied Therapeutics Reports Second Quarter 2020 Financial Results

NEW YORK, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...

August 11, 2020

Showing 1-10 of about 48 articles.

Search Results

Applied Therapeutics to be Added to NASDAQ Biotechnology Index

Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative

Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study

Applied Therapeutics Reports Third Quarter 2020 Financial Results

Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2020

Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2020 Annual Meeting

FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG

Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at 56th Annual Meeting of the European Association for the Study of Diabetes

Applied Therapeutics to Present at Citi and Baird Investor Conferences

Applied Therapeutics Reports Second Quarter 2020 Financial Results

Newswire Distribution Network & Management

About Us